ART
![July/August 2023: Second-Line Switch to Dolutegravir for Treatment of HIV Infection](https://icap.columbia.edu/wp-content/uploads/JC_July_Aug-2023-Photo-1080x675.jpg)
July/August 2023: Second-Line Switch to Dolutegravir for Treatment of HIV Infection
Article and Study Summary: Second-Line Switch to Dolutegravir for Treatment of HIV Infection Published in: N Engl J Med. 2023;388(25):2349-2359 https://www.nejm.org/doi/full/10.1056/NEJMoa2210005 Authors: Ombajo LA, Penner J, Nkuranga J, et al. Summary The...![May/June 2023: Adaptive Strategies for Retention in Care among Persons Living with HIV](https://icap.columbia.edu/wp-content/uploads/Journal-Club-May_June-2023_final-1080x675.jpg)
May/June 2023: Adaptive Strategies for Retention in Care among Persons Living with HIV
Article and Study Summary: Adaptive Strategies for Retention in Care among Persons Living with HIV Published in: NEJM Evid 2023;2(4) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200076 Authors: Geng EH, Odeny TA, Montoya LM, et al. Summary This trial used a...Implementing Six Multi-Month Dispensing of Antiretroviral Therapy in Ethiopia: Perspectives of clients and healthcare workers
Authors: Joanne E. Mantell, Jennifer M. Zech, Tsitsi B. Masvawure, Tamrat Assefa, Mitike Molla, Laura Block, Dereje Duguma, Zenebe Yirsaw, & Miriam Rabkin Abstract: Background Multi-month dispensing (MMD) of antiretroviral therapy (ART) is an integral component...![April 2021: IMPAACT 2010/VESTED trial evaluates the virological efficacy and safety of ART regimens containing DTG when started in pregnancy](https://icap.columbia.edu/wp-content/uploads/GettyImages-1208393752-1-e1619719000287-1080x675.jpg)